Market revenue in 2024 | USD 3,957.4 million |
Market revenue in 2030 | USD 3,066.8 million |
Growth rate | -4.4% (CAGR from 2025 to 2030) |
Largest segment | Eylea |
Fastest growing segment | Vabysmo |
Historical data covered | 2018 - 2023 |
Base year for estimation | 2024 |
Forecast period covered | 2025 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Eylea, Lucentis, Beovu, Vabysmo |
Key market players worldwide | Roche Holding AG ADR, Biogen Inc, Pfizer Inc, Amgen Inc, Bausch Health Companies Inc, Viatris Inc, Coherus BioSciences Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to anti-vascular endothelial growth factor therapeutics market will help companies and investors design strategic landscapes.
Eylea was the largest segment with a revenue share of 56.9% in 2024. Horizon Databook has segmented the Europe anti-vascular endothelial growth factor therapeutics market based on eylea, lucentis, beovu, vabysmo covering the revenue growth of each sub-segment from 2018 to 2030.
Growing disease burden of ophthalmic diseases in the region and increasing investments for development of treatment options are expected to drive the anti-VEGF therapeutics market in the region. Prevalence and incidence of indications, such as AMD and diabetic retinopathies, are reported to be high in the region, which can support market growth.
Currently, there are various options available for the treatment of these diseases. However, anti-VEGF therapeutics are the first choice of treatment. According to a survey, around 61% of respondents in Europe prefer Eylea for the treatment of diabetic retinopathies and DME.
Healthcare in Europe is universal, with coverage available for all approved uses. On the contrary, reimbursement for off-label drug use differs across Europe in accordance with the existence of legislation permitting off-label use.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe anti-vascular endothelial growth factor therapeutics market , including forecasts for subscribers. This continent databook contains high-level insights into Europe anti-vascular endothelial growth factor therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account